Market Overview

JPMorgan Comments On Juno Therapeutics, Celgene

Related JUNO
Vetr Crowd In Lockstep With Market In Opting To Sell Juno
20 Biggest Mid-Day Losers For Thursday
Related CELG
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Celgene Adds To Wednesday's Gain
No. 5-Ranked Biotech Bolts Higher On Drug Results (Investor's Business Daily)

On June 29, Juno Therapeutics Inc (NASDAQ: JUNO) and Celgene Corporation (NASDAQ: CELG) announced a ten-year collaboration to develop new therapies for cancer and auto-immune diseases, specifically T cell therapies. Celgene will have the option to commercialize Juno’s programs outside North America, while Juno will be have the ability to co-develop and co-promote certain Celgene therapies.

CAR T-cell therapy, or chimeric antigen receptors, is a method of treating cancer that harnesses the patient’s own immune system. A patient’s T cells are multiplied and then infused back into the patient in an attempt to fight back against the cancer. Juno currently has several CAR therapies in its pipeline aimed at different forms of leukemia and lymphoma.

According to the agreement, Celgene will make an initial investment of $1 billion in Juno. This includes buying more than nine million shares of Juno for $93 per share. At the time of the announcement, shares of Juno were trading at $46; nearly half that amount. This signal of confidence caused shares of JUNO to soar over 40 percent in pre-market trading following the announcement, though the price stabilized during the day and closed at $46.30.

The partnership will be mutually beneficial, as described by executives of both companies. Celgene CEO Bob Hugin pointed out Juno’s “impressive capabilities and technologies in the areas of T cell biology and cellular therapy.” On the other hand, Juno’s CEO Hans Bishop is looking forward to integrating Celgene’s “leading small molecule and protein capabilities that complement Juno’s advanced engineered T cell capabilities.”

Although the partnership seems to be a win for both biotechnology companies, Cory Kasimov of J.P. Morgan was more bullish on Juno than Celgene. The analyst reiterated an Overweight rating on Juno and raised his price target from $66 to $83.

Kasimov explains, “From JUNO’s perspective, this is clearly a big win; the deal provides a huge infusion of cash as well as validation for the company’s diversified approach within CAR-T, not to mention the overall potential of this nascent field.” Overall, the analyst believes the partnership will make Juno a more competitive player in the biotechnology field thanks to its new advanced capabilities.

Despite his bullishness on Juno, Kasimov reiterated a Neutral rating on Celgene with an unchanged price target of $126. The analyst views the deal with high levels of both risk and reward for Celgene, but adds that this move did not come as a surprise for Celgene.

Kasimov expects the deal to close in the third quarter. He added, “JUNO noted it plans to accelerate all the investments it is making, first and foremost in the people it hires, in addition to moving a bit faster across the pipeline and in manufacturing.”

Cory Kasimov has a 61 percent overall success rate recommending stocks with a +14 percent average return per rating.

Latest Ratings for JUNO

Feb 2017Wells FargoInitiates Coverage OnOutperform
Feb 2017WedbushInitiates Coverage OnNeutral
Dec 2016Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for JUNO
View the Latest Analyst Ratings

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: JPMorgan JPMorgan ChaseAnalyst Color Biotech Analyst Ratings General


Related Articles (CELG + JUNO)

View Comments and Join the Discussion!